NCT01671410View on ClinicalTrials.gov

Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Neonatal Abstinence Syndrome

Interventions

DRUG

oral morphine

Oral morphine for the treatment of neonatal abstinence syndrome

DRUG

sublingual buprenorphine

Sublingual buprenorphine for the treatment of neonatal abstinence syndrome

Trial Locations (1)

19107

Thomas Jefferson University Hospital, Philadelphia

All Listed Sponsors

lead

Thomas Jefferson University

OTHER

NCT01671410 - Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines | Biotech Hunter | Biotech Hunter